Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rhythm versus rate control in patients with newly diagnosed atrial fibrillation - Observations from the GARFIELD-AF registry.
Knudsen Pope M, Hall TS, Virdone S, Atar D, John Camm A, Pieper KS, Jansky P, Haas S, Goto S, Panchenko E, Baron-Esquivias G, Angchaisuksiri P, Kakkar AK; GARFIELD-AF Investigators. Knudsen Pope M, et al. Among authors: baron esquivias g. Int J Cardiol Heart Vasc. 2023 Nov 16;49:101302. doi: 10.1016/j.ijcha.2023.101302. eCollection 2023 Dec. Int J Cardiol Heart Vasc. 2023. PMID: 38020059 Free PMC article.
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
Anguita Sánchez M, Marín F, Masjuan J, Cosín-Sales J, Vázquez Rodríguez JM, Barrios V, Barón-Esquivias G, Lekuona I, Pérez-Cabeza AI, Freixa-Pamias R, Parra Jimenez FJ, Monzer Khanji Khatib M, Rafols Priu C, Sanmartín Fernández M. Anguita Sánchez M, et al. Among authors: baron esquivias g. Cardiol J. 2022;29(6):936-947. doi: 10.5603/CJ.a2022.0091. Epub 2022 Oct 6. Cardiol J. 2022. PMID: 36200548 Free PMC article.
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M, Anguita Sánchez M, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Esteve-Pastor MA, Freixa-Pamias R, Lekuona I, Pérez-Cabeza AI, Ureña I, Vázquez Rodríguez JM, Rafols Priu C, Marin F. Sanmartín Fernández M, et al. Among authors: baron esquivias g. Cardiol J. 2022;29(4):601-609. doi: 10.5603/CJ.a2022.0044. Epub 2022 May 27. Cardiol J. 2022. PMID: 35621092 Free PMC article.
Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
Rivera-Caravaca JM, Anguita Sanchez M, Sanmartín Fernández M, Rafols C, Barón-Esquivias G, Arribas Ynsaurriaga F, Freixa-Pamias R, Lekuona Goya I, Vázquez Rodríguez JM, Pérez-Cabeza AI, Cosín-Sales J, Ureña Montilla I, Álvarez-Vieitez Blanco A, Marín F. Rivera-Caravaca JM, et al. Among authors: baron esquivias g. Am J Cardiol. 2023 Sep 15;203:122-127. doi: 10.1016/j.amjcard.2023.06.105. Epub 2023 Jul 22. Am J Cardiol. 2023. PMID: 37487406 Free article.
Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry.
Barón-Esquivias G, Roldán Rabadán I, García Quintana A, Cerezo Manchado JJ, Antorrena Miranda I, Gómez-Barrado JJ, Pérez Paredes M, Santas E, Pindado Rodríguez J, Muñoz-Robles JA, Oliver-Miñarro D, Santamaría A; investigators of ETNA AF Spain. Barón-Esquivias G, et al. Future Cardiol. 2020 Sep;16(5):469-480. doi: 10.2217/fca-2020-0024. Epub 2020 Mar 31. Future Cardiol. 2020. PMID: 32228182
96 results